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Abstract
Objective: Bronchoalveolar lavage (BAL) is a diagnostic tool often used during the management of interstitial lung
diseases (ILD). However, its diagnostic value in discrimination between entities comprising the very heterogenous
group of ILD, is still a controversial issue. The objective of our study is to assess the diagnostic value of BAL in the
management of ILD, by comparing the cytological findings in BAL fluid among the different diseases of this group.
Methods: It was a retrospective, observational study of 151 patients between January 2012 and December 2015.
BAL fluid cytology was performed to analyse the distribution of leucocytes population subsets in patients with ILD.
Results: The mean age was 52.78 years; 74.83% were women. The analysis of the following main groups of
diseases was performed : sarcoïdosis (n = 30), idiopathic pulmonary fibrosis (IPF; n = 22), other idiopathic interstitial
pneumonia (non specific interstitial pneumonia, cryptogenic organising pneumonia and respiratory bronchiolitis
interstitial lung disease; n = 20) and connective tissue disease (n = 14).
Overall, out of 141 patients, 22% had sarcoïdosis, 15.6% had idiopathic pulmonary fibrosis (IPF), 14.18% had other
idiopathic interstitial pneumonia (IIP) and 9.9% had connective tissue disease (CTD). Mixed alveolitis was common
in the 4 groups, sarcoïdosis had higher proportion of lymphocytes and IPF had higher neutrophils count. However,
there was no significant statistical difference of BAL cellular count among these diseases (p > 0.05). Also, the
prevalence of studied diseases did not change with variation of BAL cellular count (p > 0.05).
Conclusion: Alone, the BAL cytological analysis has a limited value to provide substantial information that could lead
to discriminate between diseases that form ILD. Thus, it must be always associated with other diagnostic methods.
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Introduction
BAL is a non-invasive procedure performed with the
fiberoptic bronchoscope in a wedge position within the
selected bronchopulmonary segment. The examination
of cells and solutes from the lower respiratory tract
provides valuable information about diagnosis and yield
insights into immunologic, inflammatory, and infectious
processes taking place at the alveolar level [1–3]. The
cytological analysis of BAL fluid is commonly used in
the management of a variety of lung diseases especially
the large and wide group of interstial lung diseases (ILD)
[1, 4, 5]. The term of ILD consisted of acute and chronic
bilateral parenchymal infiltrative lung diseases with
variable degrees of tissue inflammation and fibrosis
when they occur in immunocompetent hosts without in-
fection or neoplasm [1]. ILD can be either of known or
unknown cause; according to the statement of the
American Thoracic Society and the European Respira-
tory Society, ILD with known cause include the pneu-
moconioses, ILD associated with connective tissue
disease (CTD-ILD), and hypersensitivity pneumonitis
(HP); ILD with unknown cause are sarcoidosis and
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idiopathic interstitial pneumonias (IIP) [1]. IIP are an-
other heterogenous entity comprising idiopathic pul-
monary fibrosis (IPF), nonspecific interstitial pneumonia
(NSIP), desquamative interstitial pneumonia (DIP), re-
spiratory bronchiolitis with interstitial lung disease
(RBILD), acute interstitial pneumonia (AIP), cryptogenic
organizing pneumonia (COP), and lymphoid interstitial
pneumonia (LIP) [1–4].
The diagnosis of ILD relies on a combination of mul-
tiple diagnostic tools, such as imaging technics (espe-
cially high resolution computed tomography (HRCT),
blood test, lung function tests, transbronchial biopsy or
lung biopsy [1, 3, 4]. All these diagnostic modalities
should be correlated to a clinical context of the patient:
physical examination, detailed clinical history, smoking
history,…etc. Transbronchial biopsy is very helpful in
the diagnosis of malignancy or granulomatous diseases
but lacks any specificity in ILD. The lung biopsy is an in-
vasive technics that can be performed via thoracoscopy
or thoracotomy, but often it can be contra-indicated in
some patients because it is associated with morbidity
and mortality [1, 3]. The diagnostic value of BAL cyto-
logical analysis in the management of ILD is still a mat-
ter of debate and controversis [1, 4, 6, 7]. Thus, the
objective of our study is to analyse BAL cytological
findings in the most common ILD in order to assess its




Over a period of 4 years (January 2012-December 2015),
we included retrospectively, 151 cases of BAL in patients
suspected of ILD, registered in the service of anatomical
and cytological pathology of Hassan II teaching hospital,
Fez Morocco. The diagnosis of ILD has been based on
confrontations of clinical, biological and cyto-histological
aspects, according to international consensus [1, 8]. All
cases of ILD have been discussed in multidisciplinary
meetings attended by diverse specialists: pathologists,
pneumologists, oncologists, radiologists, radio-oncologists
and thoracic surgeons.
BAL cellular analysis
Collected BAL fluids have been cytocentrifuged and
stained with Wright-Giemsa stain, Perls stain, and PAS
stain for total and differential cell counts. BAL cytological
analysis has been performed manually by a pathologist
specialised in cytology. Differential cell count has been
performed with identification of alveolar macrophages,
lymphocytes, neutrophils and eosinophils, or other find-
ings like tumoral cells, foreign body, mastocytes, basophils
or red blood cells.
The analysis and comparison of differential cell count
were carried out among the common ILD or group of
ILD encountered : sarcoidosis, connective tissue diseases
(CTD), idiopathic pulmonary fibrosis (IPF), nonspecific
interstitial pneumonia (NSIP), cryptogenic organizing
pneumonia (COP) and respiratory bronchiolitis with
interstitial lung disease (RBILD). NSIP, COP and RBILD
have been associated in a single groupe of other IIP, be-
cause of their small prevalence in our study, and because
of their prognostic similarities, compared to IPF.
Statistical analysis
In the descriptive analysis, qualitative variables were
expressed as absolute and relative frequencies and
quantitative variables as means and standard deviations.
Differences in BAL cytology with macrophages, lym-
phocytes and polymorphonuclear cells subsets among
groups were compared by using the one-way ANOVA
tables. Pearson’s Chi-square test was performed to assess
the prevalence changes of different ILD diseases according
to differential cell count variations. The variation of in-
flammatory cell subpopulations has been arbitrarely fixed
as intervals, according to normal values and in regard to
previous studies [1, 5, 9, 10].
All statistical analyses were performed by using SPSS
20.0 version software for Windows (SPSS, Inc., Chicago,
IL, USA). P value was considered statistically significant
at P < 0.05.














Eosinophilic pneumonia 4 (2.8)
Drug-induced pneumonitis 3 (2.1)
Infectious pneumonitis 3 (2.1)
Total 141 (100)
IPF idiopathic pulmonary fibrosis, CTD Connective tissue diseases, RBILD
respiratory bronchiolitis-associated interstitial lung disease, EAA extrinsic
allergic alveolitis, NSIP nonspecific interstitial pneumonia, COP cryptogenic
organizing pneumonia
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Results
Our study included 151 patients, with 113 females and
38 males (sex ratio Male/female = 0.33). The mean age
was 52.78 years (age variying from 15 to 80 years).
Of 151 patients, 141 had definitive diagnosis (Table 1).
Sarcoidosis was the most encountered disease, followed
by IPF. IIP (IPF, NSIP, POC and RBILD) were found 42
patients, with a prevalence of 29.79%, IPF was the most
diagnosed IIP.
Table 2 shows the cell differentials according to final
diagnoses in the main groups with ILD (sarcoidosis, IPF,
CTD and other IIP (NSIP, POC and RBILD). These dis-
eases showed mixed alveolitis (lymphocytes and neutro-
phils), sarcoidosis had the highest lymphocytes count
(38.13%) followed by CTD (29.07%). Mixed alveolitis
with predominant neutrophils count was observed in
IPF (18.23% of neutrophils). However these differences
between studied disesases were not statistically signifi-
cant as p 0.05 in all cellular counts.
Few patients (37 cases) in our study had immunophe-
notyping of CD4 and CD8 lymphocytes (Table 3). The
overall mean of CD4/CD8 ratio was 2.18. The mean
CD4/CD8 ratio was highest for sarcoidosis compared to
other diseases, it was 2.56.
The Pearson’s Chi-square test has been performed to
assess the prevalence changes of studied ILD, when BAL
differential count of cellular subpopulations varies in
certain proportions.
The Table 4 shows that the prevalence of sarcoidosis
was high when lymphocytes > 40%. The prevalence of
IPF and other IIP decreased when lymphocytes count in-
creased. However these changes in prevalence according
to lymphocytes count variation were not statistically sig-
nificant (p = 0.33).
Also, the prevalence according to neutrophils count
variation was not statistically significant (p = 0.38), as il-
lustrated in Table 5. The prevalence of sarcoidosis de-
creased when neutrophils count > 20%. The prevalence
of IPF was maximal when neutrophils range between 5
and 20%. CTD were frequently diagnosed when neutro-
phils count < 5%.
Similarly, the eosinophils count did not affect the
prevalence of studied ILD diseases (Table 6), (p = 0.05).
IPF was more freqently diagnosed when neutrophils
range between 2 and 5%, the prevalence of other dis-
eases decrased when neutrophils count > 1%.
Table 7 showed that the prevalence of all studied
ILD increased when macrophages count augments,
but these prevalence changes were not statistically
significant (p = 0.35).
Discussion
In the current study, we have tried to assess the diagnos-
tic value of BAL in ILD by analysing and comparing the
different cellular subpopulations count between the most
commonly diagnosed ILD, such as sarcoidosis, CTD and
certain IIP (IPF, NSIP, POC and RBILD). The diagnosis
Table 2 BAL cellular count in studied interstitial lung diseases (ILD)
Sarcoidosis (n = 30) IPF (n = 22) Other IIP (n = 20) CTD (n = 14) P value
Macrophages (%) 46.1 (22.87) 55.5 (23.93) 56.64 (20.62) 52.27 (32.34) 0.4
Lymphocytes (%) 38.13 (26) 26.7 (19.23) 29.07 (22.15) 30.71 (32.18) 0.23
Neutrophils (%) 14.22 (18.13) 14.97 (23.65) 13 (12.7) 15.21 (14.79) 0.82
Eosinophils (%) 1.89 (5.24) 2.39 (1.27) 1.15 (3.86) 1.57 (1.4) 0.48
Data are presented as means (standard deviation). IIP idiopathic interstitial diseases. Other IIP includes NSIP, COP and RBILD
Table 3 CD4/CD8 ratio
CD4/CD8
Mean ˂3.5 ≥3.5
Sarcoïdosis (n = 13) 2.65 9 4
IPF (n = 4) 1.5 3 1
Tuberculosis (n = 4) 1.99 4 0
EAA (n = 5) 1.41 5 0
RBILD (n = 2) 2.19 1 1
Pneumoconiosis (n = 2) 1.66 2 0
POC (n = 1) 1.7 1 0
CTD (n = 1) 1.34 1 0
Vasculitis (n = 1) 1.6 1 0
Eosinophilic pneumonitis (n = 1) 6.25 0 1
Heart diseases (n = 1) 2.8 1 0
Tumors (n = 1) 1.4 1 0
Infectious pneumonitis (n = 1) 2.35 1 0
Table 4 Prevalence of studied ILD according to lymphocytes
count variation
Lymphocytes (%)
≤20 21–40 > 40
Sarcoïdosis (n = 30) 36.7% 20% 43.3%
IPF (n = 22) 45.5% 36.4% 18.2%
Other IIP (n = 20) 50% 30% 20%
CTD (n = 14) 57.1% 14.3% 28.6%
Prevalence variation of studied ILD is not statistically significant (p = 0.33)
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of these diseases is not easy; thus it relies on a confron-
tation between clinical, biological, radiological, histo-
logical and cylogical features of the patient [1, 7, 8]. ILD
are a very heterogenous group of diseases including a
variety of clinical entities that do not share the same
prognosis [1–5]. Also, the treatment varies among dis-
eases that form the large group of ILD, hence the urge
of exact etiological diagnosis in order to ajust treatment
according to the causative disease [1, 7–13]. Unfortu-
nately, all available diagnostic tools (radiology, biology,
cytology, histology) lack any specificity [1, 2, 6, 14–16].
In our study, we found that all studied ILD were charac-
terised by mixed alveolitis with predominant lympho-
cytes and neutrophils count, sarcoidosis had the highest
lymphocytes count (38.13%). But statistical analysis
failed to show any significant difference between studied
diseases. We have also tried to know if the prevalence of
studied ILD changes with the variation of different sub-
populations count (lymphocytes, macrophages, neutro-
phils and eosinophils). However, we found that the
variation in prevalence of ILD was not significantly af-
fected by BAL differential count variation. For instance,
when lymphocytes count > 40%, the prevalence of sar-
coidosis was high, when this count ≤ 20%, the prevalence
of CTD, IPF, and other IIP, increased. When it comes to
neutrophils count, the prevalence of sarcoidosis de-
creased when neutrophils count > 20%, the prevalence of
IPF was high when neutrophils range between 5 and
20%, CTD were mostly diagnosed when neutrophils
count was lower than 5%. As mentionned above, all
these findings were not statistically significant. In the lit-
erature, it was widely reported that sarcoidosis shows
high lymphocytes count associated with CD4/CD8 > 2
[9, 16–18]. In our study, few patients (37 cases) had lym-
phocytes immunophenotyping. The mean CD4/CD8 was
2.56 for sarcoidosis. We have also found a high neutro-
phils count for IPF, as reported in the literature [2, 9]. In
the presence of a high neutrophils count associated with
a mild to moderate lymphocytes count (< 30% in gen-
eral), the diagnosis of IPF should be considered [2, 3, 9].
The diagnostic value of BAL to discriminate between
ILD is still a challenging and controversial issue. Numer-
ous studies have tried to deal with this issue, leading to
contradictory conclusions, and some authors claimed
the limited clinical usefulness of BAL cellular analysis in
ILD [6]. Welker L. et al. showed that the likelihood for
sarcoidosis increased from 33.7 to 68.1% when lympho-
cyte numbers were 30–50% and granulocyte numbers
were low; the likelihood for usual interstitial pneumonia
(UIP) increased from 15.8 to 33.3% when lymphocyte
numbers were < 30% with granulocytes elevated [9]. This
study, like many other studies pointed out the diag-
nostic value of CD4/CD8 in the diagnosis of sarcoid-
osis [6, 16–18]. Eosinophils are very rare in BAL
fluid, they range between 0 and 1%, any eosinophils
count higher than this range is pathological [1, 3, 5].
BAL eosinophilia can be found at variable degrees in
diseases like immuno-allergic pneumonia or chronic
eosinophilic pneumonia; also mild to moderate eo-
sinophilia can be found in ILD [1, 7, 11]. We found
that IPF was associated with a mild hypereosinophilia
(2.39%), in the literature it has been reported that
BAL eosinophilia associated with a mild lymphocytes
count and elevated neutrophils, is an important fea-
ture of IPF [4, 8, 9]. BAL in CTD has no particular
characteristics, often mixed alveolitis with predomin-
ant lymphocytes and neutrophils, was found [9, 19].
Despite limitations (small number of patients, retro-
spective and monocentric study), the findings in our
study prompted us to question the real utility of BAL
cellular count in ILD. In fact, we found any statistical
difference in BAL cytology between studied ILD dis-
eases. Recently, a study by Lee W et al. on 69 cases of
ILD concluded that the routine analysis of BAL lympho-
cyte subset may not provide any additional benefit for
Table 5 Prevalence of studied ILD according to neutrophils
count variation
Neutrophils (%)
< 5 5–20 > 20
Sarcoïdosis (n = 30) 40% 40% 20%
IPF (n = 22) 27.3% 45.5% 27.3%
Other IIP (n = 20) 20% 60% 20%
CTD (n = 14) 50% 21.4% 28.6%
Prevalence variation of studied ILD is not statistically significant (p = 0.38)
Table 6 Prevalence of studied ILD according to eosinophils
count variation
Eosinophils (%)
≤1 2–5 > 5
Sarcoïdosis (n = 30) 80.8% 11.5% 7.7%
IPF (n = 22) 27.3% 85.7% 0.0%
Other IIP (n = 20) 47.4% 47.4% 5.3%
CTD (n = 14) 61.5% 38.5% 0%
Prevalence variation of studied ILD is not statistically significant (p = 0.05)
Table 7 Prevalence of studied ILD according to macrophages
count variation
Macrophages (%)
< 30 30–50 > 50
Sarcoïdosis (n = 30) 26.7% 33.3% 40%
IPF (n = 22) 13.6% 27.3% 59.1%
Other IIP (n = 20) 5% 35% 60%
CTD (n = 14) 21.4% 14.3% 64.3%
Prevalence variation of studied ILD is not statistically significant (p = 0.35)
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differential diagnosis of DILDs, except for conditions
where BAL is specifically indicated, such as eosinophilic
pneumonia or sarcoidosis [6]. It has been speculated that
BAL plays an important role in the management and
follow-up of patients treated for ILD [1, 3, 10], however
another recent study by Petrosyan F et al. on 77 patients
followed for IPF, showed that pulmonary infection can
be excluded based on clinical and laboratory data and
that bronchoscopy with BAL is not mandatory in the
diagnostic work-up of suspected acute clinical deterior-
ation of IPF [20].
Despite tremendous controversis, it is widely ac-
cepted that BAL analysis alone has no diagnostic value,
confrontation with clinical and radiological features is
necessary [1]. That is why in our center, all cases of ILD
are discussed in multidisciplinary meetings (MDM), as it
is widely accepted that these meetings are very useful in
the management of ILD [21, 22]. The American Thoracic
Society (ATS) statement has been clear and realistic.
“When used in conjunction with comprehensive clinical
information and adequate thoracic imaging such as high-
resolution computed tomography of the thorax, BAL cell
patterns and other characteristics frequently provide use-
ful information for the diagnostic evaluation of patients
with suspected ILD” [1].
Conclusion
We found in the current study that there was no statisti-
cally significant difference in BAL cytology between ILD.
Thus BAL doesn’t provide any substantial information
that could lead to discriminate between entities that
form ILD. The definitive diagnosis of ILD should be
discused in MDM after confrontation between BAL
cytology and other dignostic tools.
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